Verona reports Phase IIa data for RPL554 in COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in patients with chronic obstructive pulmonary disease (COPD) showing that twice-daily 1.5 and 6 mg doses of RPL554 (VMX554, VRP554) plus Spiriva tiotropium each met the co-primary endpoint of improving peak forced expiratory volume in 1 second (FEV1) on day 3 vs. Spiriva alone (p=0.002 and p<0.001, respectively). High-dose RPL554 plus Spiriva also met the co-primary endpoint of improving average FEV1 on day 3 vs. Spiriva alone (p<0.001).

Low- and high-dose RPL554 plus Spiriva also met the secondary endpoints of achieving a faster onset of action (4.2 and 4.6 minutes, respectively, vs. 37.6 minutes, p<0.001 for both) and of reducing functional residual capacity (p<0.01 and p<0.05, respectively) vs. Spiriva alone. High-dose RPL554 plus Spiriva also met the secondary endpoint of reducing residual lung volume vs. Spiriva alone (p<0.01)...